Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 207

1.

The effects of neuraminidase inhibitors on the release of oseltamivir-sensitive and oseltamivir-resistant influenza viruses from primary cultures of human tracheal epithelium.

Yamaya M, Nadine L, Kubo H, Saito K, Saito R, Nishimura H.

J Med Virol. 2015 Jan;87(1):25-34. doi: 10.1002/jmv.23974.

PMID:
24838828
2.

Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.

Dapat C, Kondo H, Dapat IC, Baranovich T, Suzuki Y, Shobugawa Y, Saito K, Saito R, Suzuki H.

Antiviral Res. 2013 Sep;99(3):261-9. doi: 10.1016/j.antiviral.2013.06.003.

PMID:
23791870
3.

In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of influenza virus in the Japanese 2012-2013 season.

Ikematsu H, Kawai N, Iwaki N, Kashiwagi S.

J Infect Chemother. 2015 Jan;21(1):39-42. doi: 10.1016/j.jiac.2014.08.030.

PMID:
25277670
4.

Pandemic H1N1 2009 influenza virus with the H275Y oseltamivir resistance neuraminidase mutation shows a small compromise in enzyme activity and viral fitness.

Brookes DW, Miah S, Lackenby A, Hartgroves L, Barclay WS.

J Antimicrob Chemother. 2011 Mar;66(3):466-70. doi: 10.1093/jac/dkq486.

5.

In vitro neuraminidase inhibitory activities of four neuraminidase inhibitors against influenza viruses isolated in the 2010-2011 season in Japan.

Ikematsu H, Kawai N, Kashiwagi S.

J Infect Chemother. 2012 Aug;18(4):529-33. doi: 10.1007/s10156-012-0377-8.

PMID:
22370919
6.

Influenza A(H1N1)pdm09 resistance and cross-decreased susceptibility to oseltamivir and zanamivir antiviral drugs.

Correia V, Santos LA, Gíria M, Almeida-Santos MM, Rebelo-de-Andrade H.

J Med Virol. 2015 Jan;87(1):45-56. doi: 10.1002/jmv.23986.

PMID:
25042157
7.

In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of the influenza virus circulating in the Japanese 2013-2014 season.

Ikematsu H, Kawai N, Iwaki N, Kashiwagi S.

J Infect Chemother. 2015 Sep;21(9):634-8. doi: 10.1016/j.jiac.2015.05.004.

PMID:
26096495
8.

Neuraminidase Activity and Resistance of 2009 Pandemic H1N1 Influenza Virus to Antiviral Activity in Bronchoalveolar Fluid.

Ruangrung K, Suptawiwat O, Maneechotesuwan K, Boonarkart C, Chakritbudsabong W, Assawabhumi J, Bhattarakosol P, Uiprasertkul M, Puthavathana P, Wiriyarat W, Jongkaewwattana A, Auewarakul P.

J Virol. 2016 Apr 14;90(9):4637-46. doi: 10.1128/JVI.00013-16.

9.

Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.

Gubareva LV, Trujillo AA, Okomo-Adhiambo M, Mishin VP, Deyde VM, Sleeman K, Nguyen HT, Sheu TG, Garten RJ, Shaw MW, Fry AM, Klimov AI.

Antivir Ther. 2010;15(8):1151-9. doi: 10.3851/IMP1678.

PMID:
21149922
10.

Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season.

Okomo-Adhiambo M, Sleeman K, Lysén C, Nguyen HT, Xu X, Li Y, Klimov AI, Gubareva LV.

Influenza Other Respir Viruses. 2013 Sep;7(5):645-58. doi: 10.1111/irv.12113.

11.

Zanamivir-resistant influenza viruses with a novel neuraminidase mutation.

Hurt AC, Holien JK, Parker M, Kelso A, Barr IG.

J Virol. 2009 Oct;83(20):10366-73. doi: 10.1128/JVI.01200-09.

12.

Impact of mutations at residue I223 of the neuraminidase protein on the resistance profile, replication level, and virulence of the 2009 pandemic influenza virus.

Pizzorno A, Abed Y, Bouhy X, Beaulieu E, Mallett C, Russell R, Boivin G.

Antimicrob Agents Chemother. 2012 Mar;56(3):1208-14. doi: 10.1128/AAC.05994-11.

13.

Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors.

Pizzorno A, Bouhy X, Abed Y, Boivin G.

J Infect Dis. 2011 Jan 1;203(1):25-31. doi: 10.1093/infdis/jiq010.

15.

Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses.

Okomo-Adhiambo M, Nguyen HT, Sleeman K, Sheu TG, Deyde VM, Garten RJ, Xu X, Shaw MW, Klimov AI, Gubareva LV.

Antiviral Res. 2010 Feb;85(2):381-8. doi: 10.1016/j.antiviral.2009.11.005.

PMID:
19917319
16.

In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against influenza virus isolates in the 2011-2012 season in Japan.

Ikematsu H, Kawai N, Iwaki N, Kashiwagi S.

J Infect Chemother. 2014 Feb;20(2):77-80. doi: 10.1016/j.jiac.2013.07.002.

PMID:
24560563
17.

Neuraminidase inhibitor susceptibility of swine influenza A viruses isolated in Germany between 1981 and 2008.

Bauer K, Dürrwald R, Schlegel M, Pfarr K, Topf D, Wiesener N, Dahse HM, Wutzler P, Schmidtke M.

Med Microbiol Immunol. 2012 Feb;201(1):61-72. doi: 10.1007/s00430-011-0206-1.

PMID:
21688167
18.

Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses.

Hurt AC, Holien JK, Parker MW, Barr IG.

Drugs. 2009;69(18):2523-31. doi: 10.2165/11531450-000000000-00000.

PMID:
19943705
19.

Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008.

Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten RJ, Xu X, Bright RA, Butler EN, Wallis TR, Klimov AI, Gubareva LV.

Antimicrob Agents Chemother. 2008 Sep;52(9):3284-92. doi: 10.1128/AAC.00555-08.

20.

Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro.

Nguyen JT, Hoopes JD, Le MH, Smee DF, Patick AK, Faix DJ, Blair PJ, de Jong MD, Prichard MN, Went GT.

PLoS One. 2010 Feb 22;5(2):e9332. doi: 10.1371/journal.pone.0009332.

Items per page

Supplemental Content

Support Center